Effect of 0.02% and 0.01% atropine on astigmatism: a two-year clinical trial

Abstract

Background To evaluate the effects of 0.02% and 0.01% atropine eye drops on ocular and corneal astigmatism over 2 years. Methods A prospective clinic-controlled trail. The cohort study assessed 400 myopic children and divided them into three groups: 138 and 142 children were randomized to use either 0.02% or 0.01% atropine eye drops, respectively. They wore single-vision (SV) spectacles, with one drop of atropine applied to both eyes once nightly. Control children (n = 120) only wore SV spectacles. Spherical equivalent refractive errors (SER) and corneal curvature were measured every 4 months. The SER and corneal curvature were assessed by cycloplegic autorefraction and IOLMaster. Ocular and corneal astigmatism were calculated by Thibos vector analysis and then split into its power vector components, J0 (with-the-rule astigmatism) and J45 (oblique). Results After 2 years, the ocular astigmatism increased by -0.38 ± 0.29 D, -0.47 ± 0.38 D, -0.41 ± 0.35 D in the 0.02%, 0.01% atropine groups and control group, respectively (p = 0.15). The corresponding corneal astigmatism increased by -0.20 ± 0.34 D, -0.28 ± 0.35 D and -0.26 ± 0.26 D (p = 0.18). The ocular astigmatism J0 increased by 0.19 ± 0.28 D, 0.22 ± 0.36 D, 0.18 ± 0.31 D in the 0.02% atropine, 0.01% atropine and control groups, respectively (p = 0.65). The corresponding corneal astigmatism J0 increased by -0.05 ± 0.34 D, -0.11 ± 0.37 D and -0.13 ± 0.30 D (p = 0.23). There was a small but significant increase in ocular astigmatism (including J0) (all P < 0.05), but there were no changes in the ocular astigmatism J45 and corneal astigmatism (including J0 and J45) in the three groups over time (all p > 0.05). However, there were no significant differences in the changes in ocular astigmatism (including J0) among the three groups. Conclusions Treatment with 0.02% and 0.01% atropine had no clinically significant effect on ocular and corneal astigmatism over 2 years. Trial registration The First Affiliated Hospital of Zhengzhou University, ChiCTR-IPD-16008844. Registered 14/07/2016.

IMI 2023 Digest

“… 98 , 119 Nonetheless, appropriate controls were selected for the comparison group in most studies, and in the case of ortho-k and rigid corneal lens use, which cannot be easily masked, single-vision spectacles (SVSs) were used as controls. 107 However, some atropine studies 110 , 115 and one SCL study 105 used a SVS control (no drops), and thus participants would not have been masked and compliance potentially altered. In addition, many studies made no attempt at a true sham for their control group, 74 , 82 , 113 , 120 , 125 thus increasing the potential for bias.…”

Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children — a prospective, randomized, double-masked, and crossover trial

“…Details of the methods of preparation 0.01% atropine have been published elsewhere and are brie y described here [14,27]. The 0.01% atropine eye drops (3 mL sealed bottle, pH = 5.4-5.6, storage at 15-25°C, discarded eye drops after the bottle was opened for 1 month) were prepared by dissolving atropine sulfate powder (Shaoxing Minsheng Medical Co., Ltd., Zhejiang, China) with normal saline under sterile conditions and added preservative (0.3 mg/mL ethylparaben).…”

Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial

“…The degree of myopia was expressed as the SER. Using Thibos vector analysis (16)(17)(18) calculated ocular and corneal astigmatism(minimum-maximum keratometry), which were split into its power vector components, J0 (with-the-rule astigmatism) and J45 (oblique).The ocular and corneal astigmatic components are denoted as OJ0, OJ45 and CJ0, CJ45, respectively. A non-contact partial coherence interferometer (IOLMaster-500, Carl Zeiss, Germany) was used for biometric measurements (AL, ACD, and corneal curvature) after cycloplegia.…”